Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

49 results about "Kidney Toxicity" patented technology

Nephrotoxicity is one of the most common kidney problems and occurs when your body is exposed to a drug or toxin that causes damage to your kidneys.

Macrophage-polymer lipid nanoparticle composite drug delivery system, preparation method thereof and application of macrophage-polymer lipid nanoparticle composite drug delivery system in cryptococcus infection resistance

The invention discloses a macrophage-polymer lipid nanoparticle composite drug delivery system, a preparation method thereof and application of the macrophage-polymer lipid nanoparticle composite drug delivery system in cryptococcus infection resistance. According to the drug delivery system, alpha-linolenic acid (ALA), high molecular weight chitosan oligosaccharide (HCOS) and amphotericin B (AmB) are used as raw materials to construct nanoparticles AmB-PLHNs, the nanoparticles are loaded in macrophages through the phagocytosis of the macrophages, and the AmB-PLHNs (at) M1 is constructed. AmB is a common medicine for clinically treating Cn infection, but has the problems of toxic and side effects on kidney and incapability of being transferred into the center. The AmB-PLHNs (at) M1 carries AmB-PLHNs to be transferred into the brain according to the blood-brain barrier penetrating characteristic of M1 type macrophages, and the brain entering efficiency of the medicine is improved. By combining the phagocytosis of macrophages on cryptococcus, the inflammation immune regulation function of the macrophages and the bacteriostatic action of the drug-loaded nanoparticles, the drug-loaded nano-particles are used for treating Cn central infection, and the toxic and side effects of AmB are reduced.
Owner:THE NAVAL MEDICAL UNIV OF PLA

Phage lyase and application thereof

The invention discloses a bacteriophage lyase and application thereof, and particularly relates to a bacteriophage lyase with an amino acid sequence as shown in SEQ INNO.2. The bacteriophage lyase can inhibit the growth of escherichia coli, staphylococcus and salmonella, can be used as an antibacterial substance in splitting gram-negative bacteria and can be used for preparing drugs for resisting gram-negative bacteria. The lyase can be used independently or compounded with other substances, the use concentration of antibiotics can be reduced by combining the lyase with the antibiotics, toxic and side effects (such as renal toxicity of polymyxin) of drugs are reduced, and meanwhile, generation of bacterial drug resistance is delayed. After the lyase and the chitosan are combined for use, remarkable antibacterial activity is generated, the antibacterial effect can be achieved without pre-treatment on bacteria, and the practicability is improved.
Owner:GUANGDONG MEDICAL UNIV

Method for regulating human induced pluripotent stem cells to be differentiated into kidney organoid

The invention relates to the technical field of preparation of organoids, and discloses a method for regulating and controlling human induced pluripotent stem cells to differentiate into kidney organoids, which comprises the following steps: resuspending a cell cluster formed by human induced pluripotent stem cells by using a basic differentiation culture solution containing a GSK-3beta inhibitor, inoculating the cell cluster into an ultralow adsorption cell culture plate, and starting to culture, marking the time as the 0th hour of differentiation; and after culturing for 70-76 hours, replacing the basic differentiation culture solution containing the GSK-3beta inhibitor with a basic differentiation culture solution containing a Knockout TM serum substitute (KSR), and continuing to carry out differentiation culture. By adopting the method disclosed by the invention, the human induced pluripotent stem cells can be efficiently, quickly, simply, conveniently and stably subjected to directional induced differentiation into kidney organs containing podocytes, renal tubules and other structures, and the time for constructing a kidney in-vitro model can be shortened, so that the research on kidney diseases, kidney development and the like can be greatly assisted; and a powerful platform is provided for kidney toxicity assessment.
Owner:HANGZHOU HUANTEYOUJIAN BIOTECHNOLOGY CO LTD

Antibacterial peptide pa targeting multi-drug resistant gram-negative bacteria and application thereof

This invention discloses an antimicrobial peptide PA targeting multidrug-resistant Gram-negative bacteria and its application. The amino acid sequence of the antimicrobial peptide PA is shown in SEQ ID NO.1. The antimicrobial peptide PA provided by this invention has a significant antibacterial effect against multidrug-resistant Gram-negative bacteria, and has a rapid bactericidal onset, no hemolysis or cytotoxicity, does not cause nephrotoxicity after treatment, and has good biosafety. It can be used for the treatment of bacterial infections and can also be applied to other scenarios that require bactericidal or antibacterial growth inhibition.
Owner:HUAZHONG AGRI UNIV

Acute kidney injury nuclear magnetic resonance detection contrast agent as well as preparation method and application thereof

The invention discloses an acute kidney injury nuclear magnetic resonance detection contrast agent as well as a preparation method and application thereof. The lipidosome comprises a first lipid component and a second lipid component, the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine, and the second lipid component is a sterol derivative, and the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine. The molar ratio of the first lipid component to the second lipid component is (1-3): 1. According to the invention, all organic free radicals are used for replacing gadolinium ions, so that renal toxicity and systemic fibrosis risks caused by metal accumulation are eliminated, and the method is especially suitable for imaging of patients with renal insufficiency. The material synthesis process is simple, and the cost is controllable. In addition, the system is seamlessly compatible with clinical 3.0 T MRI equipment, additional hardware transformation is not needed, and popularization and application of AKI bedside rapid imaging diagnosis can be directly promoted.
Owner:SHENZHEN BAOAN DISTRICT PEOPLES HOSPITAL

Pharmaceutical composition for treating non-small cell lung cancer and use method thereof

PendingCN121197417AOrganic active ingredientsRespiratory disorderKidney ToxicityLow-dose chemotherapy
The invention provides a pharmaceutical composition for treating non-small cell lung cancer and a use method, and belongs to the technical field of tumor immunotherapy. The invention formulates a non-small cell lung cancer weak chemotherapy and anti-vascular immunity triple treatment scheme based on the combination of a low-dose chemotherapy drug pemetrexed, an immune checkpoint inhibitor and an anti-angiogenesis drug. According to the scheme, low-dose pemetrexed is combined with the anti-angiogenesis medicine and the immune checkpoint inhibitor for use, the optimal synergistic effect can be achieved, meanwhile, the renal toxicity and the myelosuppression risk are remarkably reduced, and the pemetrexed medicine composition is expected to become one of the optimal choices for driving gene negative and PD-L1 positive expression non-squamous NSCLC patients, and has a wide application prospect. The device is suitable for old people or patients with poor physical states; especially for patients with negative driver genes and positive PD-L1 expression, the traditional treatment blank is filled, and clinical data shows that survival benefits are remarkable.
Owner:SHANDONG PROVINCIAL PUBLIC HEALTH CLINICAL CENT

Method for predicting accurate dosage of polymyxin B for multi-drug-resistant severe infection patient

The invention relates to the technical field of drug information, in particular to a method for predicting the accurate dosage of polymyxin B for a multi-drug-resistant severe infection patient, which comprises the following steps: acquiring model establishment data, establishing a basic model, incorporating covariables, evaluating the model, performing external verification and simulating based on the model. According to the method provided by the invention, accurate prediction of medication of the polymyxin B is realized, and death of a patient with severe infection caused by anti-infection failure due to too low dosage of the polymyxin B is reduced; the situation that the health of a severe patient is seriously damaged due to serious renal toxicity and neurotoxicity side effects caused by overlarge dosage of the polymyxin B is avoided, and the method has important significance on precise medication of clinically refractory severe infection patients.
Owner:江西省肿瘤医院(江西省第二人民医院 江西省癌症中心)

Application of aromatic hydrocarbon receptor stimulant in preparation of medicine for treating diarrhea of weaned piglets and / or inhibiting inflammation

The invention discloses application of an aromatic hydrocarbon receptor stimulant in preparation of a medicine for treating diarrhea of weaned piglets and / or inhibiting inflammation, and belongs to the field of biological medicine. According to the present invention, with the PAS-B structural domain of the AHR as the target, the virtual screening technology, the target verification test and the weaned piglet diarrhea pharmacodynamic evaluation test are performed to determine the arctigenin as the AHR strong agonist and the anti-inflammatory drug, and the arctigenin has the good treatment effect on the weaned piglet diarrhea. Experimental results show that 10 mg / kg of arctigenin can significantly relieve diarrhea and hemafecia symptoms of weaned piglets, reduce the content of inflammatory factors in serum and intestinal tissues and improve the intestinal structure of weaned piglets, has no significant cytotoxicity, hepatorenal toxicity and intestinal epithelial cell growth inhibition effect, and can be used for preparing a feed additive for weaned piglets. The compound can be used for preparing medicines for treating diarrhea of weaned piglets. The invention provides a new raw material medicine for treating diarrhea of weaned piglets, and has great economic value and wide application prospect.
Owner:HUAZHONG AGRI UNIV

Prediction method, device and equipment for adverse reaction of chemotherapeutic drug and medium

PendingCN119170294AMedical data miningDrug referencesKidney ToxicityChemotherapy cycle
The invention provides a chemotherapeutic drug adverse reaction prediction method, device, equipment and medium, and relates to the technical field of medical information, and the method comprises the steps: obtaining a historical case data set; a plurality of adverse reaction measured values are obtained through calculation; obtaining an initial prediction model; obtaining an expected value prediction sub-model; obtaining a standard deviation prediction sub-model; acquiring chemotherapy data of the target case; and obtaining an untoward effect expected value of the target case and a corresponding standard deviation. According to the method, the adverse reaction evaluation indexes are divided into three types of myelosuppression, hepatotoxicity and kidney toxicity, the numerical value and the change value of each index are comprehensively considered, and the adverse reaction evaluation method is constructed, so that accurate quantitative description is obtained; the adverse reaction prediction model covering the expected value and the standard deviation is constructed by dividing the influence factors of the adverse reaction into the chemotherapy drugs, the chemotherapy cycle and the influence factors, so that the expected adverse reaction probability distribution can be accurately described, and a technical support is provided for quantitative analysis and prediction of the adverse reaction.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL

Brain-targeted nasal spray amphotericin B phospholipid complex as well as preparation method and application thereof

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.
Owner:SHENYANG PHARMA UNIV

Preparation method and application of non-human mammal model of hyperuricemia

PendingCN119639827AFermentationIn-vivo testing preparationsDiseaseKidney Toxicity
The invention provides a preparation method and application of a non-human mammal model of hyperuricemia. Specifically, the invention provides application of the gene editing reagent and preparation of the kit for constructing the non-human mammal model of hyperuricemia, the gene editing reagent comprises a reagent for introducing an additional second initiation codon ATG at the upstream of an initiation codon ATG of a UOX gene, and when the second initiation codon ATG is introduced, the wild type mRNA transcript level and / or the wild type UOX protein expression level of the UOX gene are / is reduced. The animal model provided by the invention is an effective animal model for simulating human hyperuricemia, and has the advantages of no renal toxicity and longer survival time. The method can be used for long-term stable research of related diseases such as hyperuricemia and can be used for screening and testing of specific drugs.
Owner:SHANGHAI JIAOTONG UNIV

Group of cyclic alkaline lipopeptide compounds, and preparation method therefor and use thereof

PCT designated stage expiredWO2024250929A1Antibacterial agentsPolymyxinsAntimicrobial drugSide chain
A cyclic basic lipopeptide compound, and a preparation method therefor and a use thereof. The compound has a structure represented by general formula I, wherein AA represents amino acid. The preparation method for a cyclic lipopeptide compound comprises the following steps: (1) reacting an Fmoc-AA-OP side chain free amino group of a protected basic amino acid with a halogenated resin to obtain Fmoc-AA-OP-resin; (2) coupling Fmoc-AA-OP-resin one by one to obtain a linear polypeptide-resin; (3) selectively removing a protective group from the linear polypeptide-resin and carrying out solid-phase cyclization on the linear polypeptide-resin to obtain a cyclic polypeptide-resin; (4) carrying out acidolysis and ether precipitation on the cyclic polypeptide-resin to obtain a cyclic polypeptide crude product; and (5) carrying out purification and / or salt conversion and lyophilization on the cyclic polypeptide crude product to obtain a cyclic polypeptide pure product. The cyclic lipopeptide compound can be used for preparing antibacterial drugs, and particularly used for preparing antibacterial drugs having improved antibacterial activity and reduced renal toxicity, comprising an antibacterial drug against carbapenem drug-resistant "super bacteria". R0-CO-AA1-AA2-D / L-AA3-ring(4-10)[Dab4-AA5-D / L-AA6-AA7-AA8-AA9-AA10] I.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI

Targeted reversible covalent ligand, radiopharmaceutical and preparation method and application thereof

The invention relates to the technical field of radiopharmaceuticals, and discloses a targeted reversible covalent ligand which comprises a targeted pharmacodynamic group (P), a reversible covalent connection bullet (RCL) and a combined radionuclide group (C), and the targeted reversible covalent ligand has a structural general formula: C-RCL-P, the reversible covalent linked bullet (RCL) is a thiol group-containing similar group linked bullet which can be reversibly combined with a disulfide bond in a target protein, and preferably comprises one of GSH, Lys-Cys, Cys, SeC, GCys and GSECys linkers. The target reversible covalent radiopharmaceutical has the following technical effects that the target reversible covalent radiopharmaceutical constructed by adopting the target reversible covalent ligand containing the RCL has excellent in-vivo pharmacokinetic characteristics, and can increase lesion uptake, lesion radioactivity residence time and imaging contrast, reduce liver and kidney uptake and reduce liver and kidney toxicity. The invention also discloses a targeted reversible covalent radiopharmaceutical as well as a preparation method and application thereof.
Owner:GUANGDONG ZHIBO BIOTECHNOLOGY CO LTD

Activated cisplatin reversible coordination complex, coordination nano-micelle thereof and application

The invention relates to the technical field of biological medicine, and discloses an activated cis-platinum reversible coordination complex, coordination nano-micelles thereof and application of the activated cis-platinum reversible coordination complex and the coordination nano-micelles. The activated cis-platinum reversible coordination complex is a complex formed by a coordination material and a metal platinum drug or an activated molecule thereof or a derivative thereof, and the coordination ratio of a coordination group in the coordination material to the metal platinum drug or the activated molecule thereof or the derivative thereof is less than or equal to 2: 1; the coordination material is a coordination phospholipid-like material or a coordination polymer material; the metal platinum medicine or the activated molecule or the derivative thereof is cis-platinum, carboplatin, lobaplatin, epithiaplatin, nedaplatin, oxaliplatin or the activated molecule or the derivative thereof. According to the activated cisplatin reversible coordination complex and the coordination nano-micelle and application thereof, the coordination nano-micelle not only can realize cisplatin controlled release regulated by iron ions, but also can reduce ferroptosis of renal tubular cells and related renal cells by chelating the iron ions, so that the renal toxicity of the cisplatin is efficiently inhibited, and the application value is wide.
Owner:TIANJIN UNIV

Bifunctional fusion protein, radionuclide marker and application thereof

The invention provides a bifunctional fusion protein radionuclide marker with a brand new structure model, which has higher labeling rate and radiochemical purity, keeps higher affinity and functional activity, and has proper molecular weight, strong tissue penetrability, good imaging effect, proper cycle half-life period and strong molecular stability. After a target carrier is radiolabeled, the target carrier still shows good affinity and is not affected, has good biological metabolic activity and clearance rate, has the effects of reducing radiation toxicity, kidney toxicity, blood toxicity and non-target organ toxicity, is well enriched in tumor cells, is beneficial to realizing diagnosis and accurate staging of tumor focuses, and can be used as a target carrier to improve the clinical application prospect. Precise radiotherapy of primary focuses and metastatic focuses is achieved, good safety and effectiveness potential are achieved, and good application prospects are achieved in the field of solid tumor treatment.
Owner:YANTAI LANNACHENG BIOTECHNOLOGY CO LTD

Amphotericin B liposome and preparation method thereof

PendingCN121059529AOrganic active ingredientsAntimycoticsCholesterolKidney Toxicity
The invention relates to the field of liposome manufacturing, and discloses an amphotericin B liposome and a preparation method thereof, and the amphotericin B liposome comprises the following components in parts by mass: 1 part of amphotericin B, 5-10 parts of hydrogenated soybean phospholipid (HSPC), 2-4 parts of cholesterol, 1-3 parts of mPEG2000-DSPE, 0.5-1.5 parts of ceramide, 0.3-0.8 part of glycyrrhetinic acid, 0.2-0.5 part of hydroxyapatite nanoparticles (nHAP) and 8-15 parts of a freeze-drying protective agent. The glycyrrhetinic acid is added, and the specific targeting effect of the glycyrrhetinic acid is utilized, so that the in-vitro binding rate of fungal cells of the lipidosome is improved, the enrichment rate of the medicine at an infected part is further improved, and the core problem of renal toxicity caused by non-targeting distribution of a traditional preparation is effectively solved; the hydroxyapatite nanoparticles adsorb medicine molecules to form a medicine-nHAP compound, and the medicine crystallization rate is greatly reduced by combining the synergistic anti-crystallization effect of the freeze-drying protective agent.
Owner:HAINAN VOCATIONAL COLLEGE OF SCI & TECH

Renal tubule 3D printing chip with peripheral capillary and application

The invention relates to the technical field of biology, in particular to a renal tubule 3D printing chip with peripheral capillary vessels and application. The invention provides a renal tubule chip for constructing a renal tubule model with peripheral capillary vessels. The invention also discloses a method for constructing a renal tubule model with peripheral capillary vessels by using the renal tubule chip. The renal tubule model with the peripheral capillary vessels constructed by the method has a renal tubule structure and the peripheral capillary vessel network of the renal tubule, the peripheral capillary vessel network of the renal tubule can be highly simulated from two aspects of an anatomical structure and a physiological process, and a more bionic renal tubule chip model is provided; an animal model and a traditional two-dimensional culture mode can be replaced, and a more accurate platform is provided for in-vitro simulated drug kidney toxicity evaluation, renal function mechanism research, kidney disease engineering modeling and kidney disease treatment drug effectiveness test.
Owner:UNIV OF SCI & TECH OF CHINA

Preparation method of cis-platinum acylating chloride modified blood purification filter membrane and corresponding purification membrane

The invention discloses a preparation method of a cis-platinum acylating chloride modified blood purification filter membrane and a corresponding purification membrane, and belongs to the technical field of medicines. The inventor of the application finds a blood purification membrane which can provide a blood purification effect and can also achieve an anti-cancer effect through administration of anti-cancer drugs through a large number of experiments and explorations. The cis-platinum can be effectively combined with the blood purification membrane, the cis-platinum is released from the blood purification filter membrane after being in contact with blood, the cis-platinum reaches cancer cells along with the blood to achieve the anti-cancer effect, meanwhile, the blood purification membrane can also remove metabolites generated in the anti-cancer process, and the anti-cancer effect is achieved. According to the preparation method and the corresponding purification membrane, the binding rate of cis-platinum and polyether sulfone can be increased, and the preparation yield is increased. The cis-platinum acylating chloride modified blood purification membrane prepared by a chemical grafting method has the effect of slowly releasing cis-platinum, and is particularly suitable for blood purification treatment of tumor patients.
Owner:HUNAN PROVINCIAL PEOPLES HOSPITAL

Polymyxin B therapeutic drug monitoring method and application thereof

The invention discloses a polymyxin B therapeutic drug monitoring method and application thereof, which can be used for monitoring PB renal toxicity, and has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result. The method comprises the following steps: (1) acquiring the concentrations of the following components of polymyxin B in a biological sample: polymyxin B1, polymyxin B2, polymyxin B3 and isoleucine-polymyxin B1; (2) taking one or more of the following concentration ratios as monitoring data: (polymyxin B + polymyxin B3) / polymyxin B, (polymyxin B1 + isoleucine-polymyxin B1) / (polymyxin B + polymyxin B3), isoleucine-polymyxin B1 / (polymyxin B + polymyxin B3), polymyxin B1 / (polymyxin B + polymyxin B3), polymyxin B1 / (polymyxin B + polymyxin B3), polymyxin B1 / (polymyxin B + polymyxin B3), and polymyxin B1 / polymyxin B; and the isoleucine-polymyxin B1 / polymyxin B, and comparing the monitoring data with a cutoff value (Cuff).
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Method for screening depleted uranium renal toxicity action target and targeted drug

The invention relates to a method for screening depleted uranium renal toxicity action targets and targeted drugs, which comprises the following steps of: 1, searching the action targets related to depleted uranium renal toxicity in a target database, selecting the targets of which the correlation is greater than 10.0, and then performing de-weighting integration to obtain the depleted uranium renal toxicity action targets; the method comprises the following steps: performing protein-protein interaction analysis on uranium-depleted kidney toxicity action targets, hiding free targets, then analyzing unhidden targets to obtain a protein-protein interaction result, obtaining a contribution value of protein according to the protein-protein interaction result, and selecting a core target according to the contribution value; and 3, screening the targeted drug from the drug database based on the core target spot, and classifying and analyzing the screened targeted drug. Through the screening method provided by the invention, the action target of the depleted uranium renal toxicity and the targeted drug for preventing and treating the depleted uranium renal toxicity can be predicted.
Owner:CHINA INST FOR RADIATION PROTECTION

Methods for evaluating renal toxicity

The present disclosure provides a method for evaluating the renal toxicity of a test substance as an improved in vitro evaluation system for evaluating the renal toxicity of a substance, such as a compound, the method comprising the step of contacting the test substance with a renal organoid, higher cytotoxicity of the test substance indicates that the test substance may have renal toxicity.
Owner:KYOTO UNIV +1

Radix puerariae and agkistrodon acutus venom wine and preparation method thereof

PendingCN118987072Afood safetySignificant hangover-relieving and liver-protecting activityDigestive systemAntinoxious agentsPhospholipaseKinin
The invention provides radix puerariae and agkistrodon acutus venom wine and a preparation method thereof, and relates to the technical field of health care wine. The radix puerariae and agkistrodon acutus venom wine comprises the following components: 0.2-0.3 g / L of radix puerariae ethanol extract, 2-3 g / L of refined agkistrodon acutus venom and the balance of sorghum liquor with the alcoholic strength of 50-55 degrees. According to the refined agkistrodon acutus venom, water-insoluble toxic factor components such as pathogenic microorganisms and viruses and toxic proteins such as cytotoxin and hemorrhagic toxin carried by the venom are removed through crude preparation and refining, and a radix puerariae ethanol extract is further added to neutralize toxic substances such as denatured cytotoxin, hemorrhagic toxin, phospholipase A2, protease and kinin; the processed agkistrodon acutus poison wine does not have bleeding, edema, muscle toxicity, liver toxicity and kidney toxicity.
Owner:XUANEN COUNTY ZHAOLIYUAN SNAKE BIOTECHNOLOGY CO LTD +1

Medicament and method for relieving inflammatory response of chronic nephropathy by composition for regulating intestinal flora

PendingCN121243234APowder deliverySolution deliveryOral suspensionsKidney Toxicity
The invention relates to the technical field of medicaments, and discloses a medicament and a method for relieving inflammatory response of chronic nephropathy by a composition for regulating intestinal flora, the medicament takes'probiotics, prebiotics and postbiotics' as a core, the probiotics contain bifidobacterium lactis and Akk bacteria, the prebiotics are fructo-oligosaccharide-inulin mixture, the postbiotics are butyrin, and the prebiotics and the postbiotics are mixed uniformly. Astragalus polysaccharide / lycium barbarum polysaccharide can be added for synergistic interaction; dosage forms of the enteric capsule, the powder and the oral suspension are divided into enteric capsules, powder and oral suspension, the enteric capsule is suitable for different people groups, inflammation is relieved by repairing intestinal barriers, inhibiting NF-kB channels and optimizing flora, after 12-24 weeks of administration, serum IL-6, TNF-alpha and hs-CRP are reduced by 15%-55%, renal functions and cardiovascular complications are synchronously improved, the enteric capsule is free of kidney toxicity, the adverse reaction rate is smaller than or equal to 5%, and the enteric capsule is suitable for long-term intervention of CKD inflammation.
Owner:THE 7TH PEOPLES HOSPITAL OF ZHENGZHOU

Nucleoside derivatives for the treatment of cancer and use thereof

The application discloses a nucleoside compound with a novel structure, a salt of the nucleoside compound and a preparation method of the nucleoside compound. The nucleoside compound and the salt thereof exhibit a strong inhibitory effect on tumor proliferation in vivo, and do not exhibit obvious side effects. Meanwhile, the compound of the application does not have obvious stomach irritation and kidney toxicity, and shows a good medical application prospect in the treatment of cancer.
Owner:NANJING ZHIHE MEDICINE TECH CO LTD

Reagent for treating acute kidney injury caused by contrast

The present invention provides a pharmaceutical composition for protecting the kidney or for treating an acute kidney injury caused by a contrast agent by reducing renal toxicity caused by a contrast agent, comprising a compound of Chemical Formula 1, which is a pyrazole derivative or a pharmaceutically acceptable salt thereof.
Owner:APTABIO THERAPEUTICS INC

Application of NK (Natural Killer) cells in preparation of medicine for treating fibrotic diseases

The invention relates to the field of cell therapy, in particular to application of NK cells in preparation of drugs for treating fibrosis diseases. The invention discloses application of NK (natural killer) cells in preparation of medicines for treating fibrosis diseases, and compared with nintedanib or pirfenidone, the NK cells have equivalent or even better effects in treatment of pulmonary fibrosis diseases, are higher in safety and do not cause side effects such as hepatotoxicity or renal toxicity. Also disclosed is a method of treating a subject suffering from a fibrotic disease by administering one or more NK cells to the subject.
Owner:SHENZHEN GENOCURY BIOTECH CO LTD

Application of schizandrin B and derivative thereof in preparation of medicine for resisting aristolochic acid-induced renal toxicity diseases and medicine composition for resisting aristolochic acid-induced renal toxicity

The invention provides application of schizandrin B and a derivative thereof in preparing a medicine for resisting renal toxicity diseases caused by aristolochic acid, and a pharmaceutical composition containing the schizandrin B and the derivative thereof for resisting renal toxicity caused by aristolochic acid. A mouse suffering from acute renal toxicity injury caused by aristolochic acid is taken as a model, and the protective effect of schisandrin B and the derivative thereof on the mouse suffering from acute renal toxicity caused by aristolochic acid is researched by combining metabonomics and proteomics. It is found that the combined use of schisandrin B and / or schisandrin B derivatives can effectively protect the renal function of mice, and serum creatinine (Cr) and urea nitrogen (BUN) are significantly reduced; the injury of aristolochic acid to the kidney of the mouse is relieved, and the renal tubular necrosis, tubular and renal tubular dilatation and the like are improved; protein expression abnormality and metabolic abnormality of mouse kidneys caused by aristolochic acid are remarkably reversed, and renal function impairment and renal tissue injury caused by aristolochic acid are remarkably reduced. The schisandrin B and the derivative thereof have a remarkable protection effect on acute renal toxicity injury caused by aristolochic acid.
Owner:GUANGDONG FOOD & DRUG VOCATIONAL COLLEGE

Lc-ms method for quantification of arginine metabolites and its application in cantharidin toxicity

PendingCN122150460AComponent separationMetaboliteKidney Toxicity
The application discloses a method for quantitatively analyzing 21 arginine synthesis metabolites in mouse liver, kidney and serum based on liquid chromatography-mass spectrometry technology and application of the method in cantharidin hepatorenal toxicity research. The method comprises the following steps: preparing 21 metabolites and two internal standard solutions; optimizing mass spectrometry multiple reaction monitoring parameters; performing sample analysis after protein precipitation by acetonitrile, nitrogen blowing dry and 50% methanol water reconstitution; and establishing eight concentration level standard curves and adopting a weighted least square method to fit a linear equation. Methodology verification shows that the linear relationship of each metabolite is good (r 2 >0.99), and the precision, accuracy, matrix effect, recovery rate and stability all meet the requirements of biological sample analysis. The method has simple sample pretreatment, high sensitivity and strong specificity, is successfully applied to determination of the content of 21 arginine metabolites in a mouse hepatorenal toxicity model caused by cantharidin, and provides a reliable analysis tool for arginine metabolism research and cantharidin toxicity mechanism exploration.
Owner:ZUNYI MEDICAL UNIVERSITY

Purine nucleoside phosphamide ester ZL-492 and application thereof in antiviral drugs

PendingCN121627784AOrganic active ingredientsSugar derivativesPurineKidney Toxicity
The invention discloses a purine-like nucleoside phosphamide ester ZL-492 and an application of the purine-like nucleoside phosphamide ester ZL-492 in an antiviral drug. The purine-like nucleoside phosphamide ester ZL-492 is obtained by taking a compound 1 and a compound 2 as raw materials and reacting in an organic solvent in the presence of a magnesium catalyst, and the chemical structural formula of the purine-like nucleoside phosphamide ester ZL-492 is shown in the specification. Researches show that the purine-like nucleoside phosphamide ester ZL-492 has a good application prospect in the aspect of resisting HIV-1 virus infection, especially HIV-lucc / HBX2 and HIV-lucc / JRFL viruses, and the application range of the purine-like nucleoside phosphamide ester ZL-492 in the aspect of resisting HIV-lucc / HBX2 and HIV-lucc / JRFL viruses is widened. The compound has the advantages of remarkably improving the activity of nucleoside drugs, improving the oral absorption efficiency, reducing the administration dosage and frequency, reducing the blood toxicity and kidney toxicity and the like.
Owner:HENAN NORMAL UNIV +1

Amino ferrocene modified black phosphorus compound containing stable free radicals as well as preparation method and application of amino ferrocene modified black phosphorus compound

PendingCN120514880ANMR/MRI constrast preparationsEmulsion deliveryMRI contrast agentGadolinium-based Contrast Agent
The invention relates to an amino ferrocene modified black phosphorus compound containing stable free radicals and a preparation method and application thereof.The amino ferrocene modified black phosphorus compound containing the stable free radicals is obtained by covalently modifying the surface of black phosphorus with amino ferrocene, and the amino ferrocene and the black phosphorus are combined through a P-C-N bond; the compound contains stable free radicals and has room-temperature ferromagnetism. The amino ferrocene modified black phosphorus compound containing the stable free radicals contains the stable free radicals, has room-temperature ferromagnetism, low toxicity and high biological safety, has no renal toxicity and brain deposition risk compared with a traditional gadolinium-based contrast agent, has saturation magnetization (Ms) three times of that of SPIONs under the condition of the same mass Fe content, and has a good application prospect. When in use, the required iron concentration is extremely low, so that cell injury and organ failure can be avoided to a great extent, and the compound can be used for an MRI contrast agent.
Owner:WUHAN UNIV OF SCI & TECH